Newsletter
Chemical manufacturing company Anupam Rasayan is acquiring up to 74.2% stake in Mumbai-based pharma company Bliss GVS Pharma for nearly ₹1,370 crore.
Bliss GVS makes a wide range of pharmaceutical products including tablets, capsules, syrups, creams, injectables and other dosage forms that are sold across India and global markets.
Why is this deal important: Anupam Rasayan has traditionally been strong in the speciality chemicals space, which basically means it supplies key ingredients used in drug manufacturing.
Together, the companies are trying to build a full-stack pharma platform, from raw ingredients to finished medicines.
The acquisition also strengthens Anupam’s presence in markets like the US and Europe and fits into its bigger strategy of becoming a global life sciences and speciality pharma player.
Big picture: pharma-linked chemical companies are currently seeing stronger growth than the broader chemicals sector.
Mint’s September-quarter earnings analysis showed that a group of pharma-linked specialty chemical and CDMO-focused companies posted around 7% YoY sales growth, compared to roughly 4% growth for non-pharma chemical companies.
Mint
